KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Change in Receivables (2017 - 2026)

Aquestive Therapeutics has reported Change in Receivables over the past 9 years, most recently at $6.0 million for Q4 2025.

  • For Q4 2025, Change in Receivables rose 356.63% year-over-year to $6.0 million; the TTM value through Dec 2025 reached $10.4 million, up 1048.08%, while the annual FY2025 figure was $10.4 million, 1048.08% up from the prior year.
  • Change in Receivables for Q4 2025 was $6.0 million at Aquestive Therapeutics, up from -$63000.0 in the prior quarter.
  • Over five years, Change in Receivables peaked at $7.7 million in Q1 2022 and troughed at -$8.2 million in Q3 2022.
  • A 5-year average of $517600.0 and a median of $635500.0 in 2021 define the central range for Change in Receivables.
  • Biggest five-year swings in Change in Receivables: crashed 2132.69% in 2024 and later surged 2228.57% in 2025.
  • Year by year, Change in Receivables stood at -$1.4 million in 2021, then crashed by 343.92% to -$6.1 million in 2022, then surged by 98.29% to -$104000.0 in 2023, then crashed by 2132.69% to -$2.3 million in 2024, then surged by 356.63% to $6.0 million in 2025.
  • Business Quant data shows Change in Receivables for AQST at $6.0 million in Q4 2025, -$63000.0 in Q3 2025, and $1.3 million in Q2 2025.